EBSCO Clinical Decisions has extended access to its generative AI-powered solution, Dyna AI, making it available to individual subscribers of DynaMedex®. This expansion enables clinicians to receive expert-curated, evidence-based clinical guidance without requiring institutional access. Initially launched in July 2024, with mobile capabilities added in October 2024, Dyna AI is now accessible on any device for individual users.
Dyna AI leverages generative artificial intelligence to deliver timely and reliable information at the point of care. Its integration into DynaMedex reflects EBSCO Clinical Decisions’ broader mission to enhance clinical decision-making by reducing information overload and improving the speed at which healthcare professionals can obtain critical insights. The system provides clear citations and concise answers grounded in the organization’s proprietary evidence-based content.
By introducing individual access, EBSCO Clinical Decisions addresses the growing need for streamlined, personalized support in clinical environments. Dyna AI assists users in identifying the most relevant information efficiently, offering a tailored experience designed to meet the practical needs of healthcare professionals working across varied contexts and specialties.
This update marks a significant shift in the availability of advanced clinical decision support tools, making high-quality resources available beyond the institutional setting. The expansion is part of EBSCO Clinical Decisions’ ongoing strategy to support clinicians with technology that reduces the time spent searching for answers and enhances the quality of patient care.
A limited trial is currently offered for individual clinicians in the United States, allowing users to explore Dyna AI’s functionality and evaluate its impact on their clinical workflows.
Click here to read the original press release.
More News in this Theme
